Actinium Pharmaceuticals, Inc.
ATNM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $37,888 | $135,148 | $257,112 | $123,614 |
| - Cash | $72,904 | $76,677 | $108,910 | $77,829 |
| + Debt | $1,573 | $2,113 | $2,581 | $310 |
| Enterprise Value | -$33,443 | $60,584 | $150,783 | $46,095 |
| Revenue | $0 | $81 | $1,030 | $1,144 |
| % Growth | -100% | -92.1% | -10% | – |
| Gross Profit | -$811 | $81 | $1,030 | $620 |
| % Margin | – | 100% | 100% | 54.2% |
| EBITDA | -$37,432 | -$51,130 | -$33,405 | -$24,250 |
| % Margin | – | -63,123.5% | -3,243.2% | -2,119.8% |
| Net Income | -$38,243 | -$48,818 | -$33,017 | -$24,774 |
| % Margin | – | -60,269.1% | -3,205.5% | -2,165.6% |
| EPS Diluted | -1.27 | -1.83 | -1.37 | -1.2 |
| % Growth | 30.6% | -33.6% | -14.2% | – |
| Operating Cash Flow | -$33,072 | -$47,335 | $8,644 | -$20,866 |
| Capital Expenditures | -$11 | -$153 | -$366 | -$133 |
| Free Cash Flow | -$33,083 | -$47,488 | $8,278 | -$20,999 |